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Abstract: Co-crystallization is a promising approach to improving both the solubility and the
dissolution rate of active pharmaceutical ingredients. Crystal structure determination from powder
diffraction data plays an important role in determining co-crystal structures, especially those generated
by mechanochemical means. Here, two new structures of pharmaceutical interest are reported: a 1:1
co-crystal of furosemide with urea formed by liquid-assisted grinding and a second polymorphic
form of a 1:1 co-crystal of carbamazepine with indomethacin, formed by solvent evaporation.
Energy minimization using dispersion-corrected density functional theory was used in finalizing both
structures. In the case of carbamazepine:indomethacin, this energy minimization step was essential
in obtaining a satisfactory final Rietveld refinement.
Keywords: co-crystal; powder diffraction; global optimization; DFT; pharmaceuticals;
Rietveld refinement
1. Introduction
In pharmaceutical science, poor solubility and a low dissolution rate in an aqueous environment
can limit the usefulness of an active pharmaceutical ingredient (API). Increasingly, new chemical
entities have poor aqueous solubility, and this has prompted researchers to develop strategies to
overcome this limitation. Although salt formation is a widely used approach to improve solubility,
it is not applicable to the many APIs that are neutral molecules. Attempts to use amorphous APIs are
hindered by issues of thermodynamic instability. Crystal engineering [1] offers an alternative approach,
whereby one seeks to “tune” the physicochemical properties of an API by forming a multicomponent
crystal of the API with a complementary molecule called a coformer. Hundreds of coformers classified
as “generally regarded as safe” are available for use in pharmaceutical formulations.
Although co-crystals have been widely studied, the definition of a co-crystal varies from study
to study. The United States Food & Drug Administration states that pharmaceutical co-crystals are
“crystalline materials composed of two or more different molecules, typically an active pharmaceutical
ingredient and a co-crystal former (‘coformers‘), in the same crystal lattice”, and that “from a physical
chemistry and regulatory perspective, co-crystals can be viewed as a special case of solvates and
hydrates, wherein the second component, the coformer, is not a solvent (including water), and is typically
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nonvolatile” [2]. The two (or more) molecules in the co-crystal interact by nonionic, noncovalent
interactions such as hydrogen bonding, pi–pi stacking and van der Waals interactions, differentiating
them from salts that involve ionic interactions.
Although co-crystals possess many potential academic and industrial advantages, screening for
co-crystals is still challenging. With the high number of coformers available, predictive models for
co-crystallization, such as the knowledge-based method developed by Wood et al. [3], are highly
valuable. The actual preparation of co-crystals can be carried out by a number of different methods [4].
For example, solution-based methods, including evaporation, cooling, antisolvent, and slurry
crystallization, can lead to the growth of single crystals suitable for analysis by X-ray diffraction.
However, controlling the factors which affect co-crystallization using these methods is critical and the
failure to obtain single crystals is not uncommon. Mechanochemical methods, including neat (dry)
co-grinding and liquid-assisted grinding, offer an alternative method of manufacture [5]. The addition
of a small amount of a solvent in liquid-assisted grinding increases the rate of co-crystallization by
a process called solution-mediated phase transformation [6]. However, mechanochemical methods
inherently produce only polycrystalline products, and as such, crystal structure determination from
powder diffraction data methods [7–10] has an important role to play in the structural characterization
of these products.
The very nature of co-crystals (i.e., multicomponent systems with generally large numbers of
atoms in the asymmetric unit) means that they present a significant challenge to powder-based
approaches, and the limited information content of a powder X-ray diffraction (PXRD) pattern dictates
that particular attention has to be paid to the fine detail of the refined crystal structure, e.g., the positions
of those hydrogen atoms involved in hydrogen bonding within the crystal structure.
This work reports for the first time the crystal structures of two co-crystals of pharmaceutical
interest, generated as part of a program of work on the application of structure determination from
powder diffraction data methods to co-crystals. One involves the use of liquid-assisted grinding to
form a 1:1 co-crystal (hereafter referred to as FUR:URE) of the practically water-insoluble diuretic
furosemide with the widely used coformer urea. The existence of a 1:1 form has been previously
reported [11], but its crystal structure has not been determined until now. The other uses solvent
crystallization to obtain a second polymorphic form of a 1:1 carbamazepine:indomethacin co-crystal
(hereafter referred to as CBZ:IND form II). Of particular interest, given the complexity of the systems
being studied, is the use of dispersion-corrected density functional theory (DFT-D) not only as a means
of crystal structure validation, but also as a valuable part of the structure refinement process.
2. Materials and Methods
Furosemide (FUR), urea (URE), carbamazepine (CBZ, form III), and indomethacin (IND, γ form)
were obtained from Sigma Aldrich UK. For FUR:URE, a Retsch MM400 ball mill was used to perform
60 min of liquid-assisted grinding of a 1:1 molar ratio mixture of FUR and URE in a 50 mL grinding jar,
with two 5 mm stainless steel grinding balls and a few drops of acetone. The resultant material was
stored for 3 weeks in a sealed glass vial at 22 ◦C prior to PXRD analysis. For CBZ:IND form II, a 1:1
molar ratio of CBZ form III and γ-IND was dissolved in ethyl acetate and polycrystalline material
recovered via solvent evaporation.
PXRD was carried out using a Bruker D8 Advance diffractometer equipped with a LynxEye
detector and monochromatic Cu Kα1 (λ = 1.54056 Å) radiation, operating in transmission capillary
mode. Powdered samples were filled in 0.7 mm borosilicate glass capillaries, and data were initially
collected over an angular range of 4 to 70◦ 2θ with a step size of 0.017◦. Where data for full structure
determination were required, a variable-counting time scheme [12] was used. In the case of FUR:URE,
the total data collection time was 18 h (see Table 1); in the case of CBZ:IND form II, the total data
collection time was scaled to 42 h.
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Table 1. The variable-counting time scheme used for the data collection on sample FUR:URE.
2θ Start/◦ 2θ End/◦ Time/s Step Size/◦
4.0 20.5 5 0.017
20.5 37.0 10 0.017
37.0 53.5 16 0.017
53.5 70.0 25 0.017
Structure indexing and structure solution were performed using the DASH software
package [13–15]. The starting molecular models used in the DASH global optimization procedure were
obtained directly from the Cambridge Structural Database (CSD) [16] and are summarized in Table 2.
Solved crystal structures were subjected to rigid-body Rietveld refinement [17] using TOPAS [18].
Table 2. Molecular structures and Cambridge Structural Database (CSD) REFCODEs for the materials
used in this work.
Compound Structure REFCODE Torsional DoF 1
Furosemide
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1 Torsional DoF = torsional degree of freedom, i.e., a torsion angle that is free to rotate, thus altering the conformation
of the molecule, and whose angular value is therefore optimized during the structure determination process.
Note that ring torsions and torsions that affect only the positions of hydrogen atoms are not optimized, as the former
are treated as fixed and the latter do n t significantly affect the calculated powde X-ray diffraction (PXRD) data.
Periodic density functional theory with van der Waals dispersion corrections (DFT-D) was
used for geometry optimization of FUR:URE and CBZ:IND form II. The Perdew–Burke-Ernzerhof
functional was used with projector-augmented wave pseudopotentials and the Grimme D3 correction,
as implemented in the pw.x executable of the QuantumEspresso program [19,20]. The lengths of bonds
involving hydrogen atoms were norm lized using Mercury CSD [21], and input files fo pw.x were
then reated fro thes ormalized CIFs using the cif2qe script of Q antumE presso. Auto atic k-point
sampling was used; the ki etic en rgy cutoffs for plane wave and charge density were 50 and 400
Ry, respectiv ly. The convergence thr sh lds on total energy and forces were set to 0.0001 and 0.001
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a.u., respectively. Initial geometry optimizations were carried out with lattice parameters fixed at
their crystallographic values, with subsequent variable cell geometry optimizations starting from the
endpoint of the fixed-cell calculations. All calculations were carried out on a Dell Precision T7810
workstation equipped with two 2.40 GHz 8-core Intel Xeon E5-2630 v3 CPUs, running the Microsoft
Windows 10 operating system and using the Windows Subsystem for Linux feature to allow the
Linux-compiled, MPI-enabled pw.x executable to utilize multiple cores.
3. Results
The crystallographic data for the FUR:URE and CBZ:IND form II co-crystals, as refined against
PXRD data, are reported in Table 3.
Table 3. Molecular structures and CSD REFCODES for the materials used in this work.
Crystallographic Data FUR:URE CBZ:IND Form II
Empirical formula C12H11ClN2O5S·CH4N2O C15H12N2O·C19H16ClNO4
Temperature (K) 298 298
Sample formulation Powder Powder
Molar mass, g mol−1 390.80 594.06
Crystal system Triclinic Monoclinic
Space group P-1 P21/n
a (Å) 4.87321(17) 5.1257(2)
b (Å) 11.0689(3) 23.3627(16)
c (Å) 15.8709(4) 23.5774(13)
α (◦) 80.4004(18) 90
β (◦) 84.737(2) 91.212(5)
γ (◦) 83.213(3) 90
Volume (Å3) 835.92(4) 2822.8(3)
Zero point (◦) 0.0149(5) 0.0045(8)
Z, Z’ 2, 1 4, 1
2θ range (◦) 4 to 70 4 to 70
No. of unique reflections 744 1232
No. of parameters 62 43
R factors
Rwp (Pawley) = 1.62% Rwp (Pawley) = 1.29%
Rwp (Rietveld) = 2.84% Rwp (Rietveld) = 2.92%
CCDC Deposition Number * 1970312 1970317
* CCDC 1970312 and 1970317 contain the crystallographic data. The data can be obtained free of charge from The
Cambridge Crystallographic Data Centre via www.ccdc.cam.ac.uk/structures.
4. Discussion
Both structures were initially solved with relative ease using the simulated annealing (SA)
approach embodied in the DASH software. In the case of FUR:URE, the ratio χ2SA/χ
2
Pawley was around
2, a strong indication that the structure had been solved [13]. In the case of CBZ:IND form II, this ratio
was significantly higher, at around 10, indicating that the best DASH solution was still some distance
from the global minimum in χ2 space. The initial visualization of the DASH solutions using Mercury
showed that both putative crystals exhibited feasible molecular conformations and packing.
For FUR:URE, our standard approach of performing a rigid-body Rietveld refinement in TOPAS,
starting from the best DASH solution, allowing positional, orientational, and torsional degrees of
freedom to refine, proceeded straightforwardly, giving an excellent fit to the data (Rwp = 3.50%).
A 4th order spherical harmonic correction for preferred orientation was included in this refinement.
Optimization of this structure using DFT-D gave a structure that, after another round of rigid body
Rietveld refinement, gave an even better fit to the data (Rwp = 2.84%, Figure 1). A variable-cell
DFT-D optimization of this final rigid-body refined structure resulted in only a small root mean square
deviation from its starting position (0.055 Å; 15 molecule overlay performed using the crystal packing
similarity feature of Mercury), a value well below the upper limit suggested by van de Streek and
Crystals 2020, 10, 42 5 of 10
Neumann for a correctly determined structure [22]. That this crystal structure (Figure 2) is that of the
form reported previously is evidenced by the visual agreement between our PXRD data and the PXRD
data shown in Figure 9 of Reference [11].
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Figure 2. The crystal structure of FUR:URE, viewed down the a-axis. The contents of three unit cells
along b and two unit cells along c are displayed, showing the layering of the urea molecules between
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Crystals 2020, 10, 42 6 of 10
In the case of CBZ:IND form II, close inspection of the solved structure gave cause for concern.
Aside from the fact that a rigid-body refinement in TOPAS did not give a satisfactory fit (Rwp = 5.30%),
it was noted that one of the hydrogen atoms of the carbamazepine amide group was not involved in
any hydrogen bonding (Figure 3a). Furthermore, it was noted that by rotating both this group and
the indomethacin carboxylic acid by 180◦, the core dimer motif was maintained whilst allowing both
amide hydrogen atoms to now participate in hydrogen bonding (Figure 3b).
Given the limited resolution of the PXRD data set used for the real-space structure solution and
the approximately equal scattering power of both configurations shown in Figure 3, it was deemed
quite likely that the DASH solution had settled in a local minimum and that the correct configuration
was in fact that shown in Figure 3b. Rotation of the two groups within the crystal structure was
achieved using the “mode fit” functionality of Olex2 [23], but this updated structure still did not give a
satisfactory fit in a rigid-body Rietveld refinement. A DFT-D geometry optimization of this updated
structure gave a structure which then gave an excellent fit (Rwp = 2.92%, Figure 4) in a rigid-body
Rietveld refinement that included a 2nd order spherical harmonics correction for preferred orientation.Crystals 2020, 10, x FOR PEER REVIEW 7 of 11 
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A variable-cell DFT-D optimization of this final rigid-body refined structure resulted in only a
small root mean square deviation (0.064 Å). The examination of the final refined structure (Figure 5)
showed some significant changes in the core geometry of the indomethacin molecule, distinct from
the purely conformational changes that result from torsion angle optimization in DASH and TOPAS.
Of particular note is a change in the geometry of the chlorobenzyl group, with (a) a bond angle
N1–C9–C10 opening from 116.80◦ (as seen in INDMET03) to 120.06◦ and (b) the disposition of Cl1 and
C9 relative to the mean plane of the C10–C11–C12–C13–C14–C15 ring being altered (see Table 4).
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Figure 5. The crystal structure of CBZ:IND form II, viewed down the a-axis. The hydrogen bonds
shown as dashed blue lines correspond to the ones indicated in Figure 3b.
Table 4. Distances of atoms Cl1 and C9 to the mean plane of the C10–C11–C12–C13–C14–C15 benzene
ring for the final CBZ:IND structure reported h re a the INDMET03 structure.
Atom CBZ:IND Form II INDMET03
Cl 1 0.118 Å 0.058 Å
C 9 0.234 Å 0.119 Å
Taken together, these geometry changes affect the location of a significant amount of X-ray
scattering power, explaining why the initial rigid-body Rietveld refinement based on the starting
INDMET03 geometry was unsuccessful.
The core hydrogen bonding motifs are essentially the same in both the previously reported
CBZ:IND form I [24] and CBZ:IND form II, taking the general form illustrated in Figure 3b, i.e., a central
R22(8) synthon and an N–H···O hydrogen bond between the amide of the CBZ and the oxygen of the
4-chlorobenzoyl group of the IND. The density of form II (1.398 g cm−3) is higher than that of form I
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(1.351 g cm−3), which is indicative of more efficient packing in form II. The melting point of form II
(151 ◦C) exceeds that of form I (144 ◦C), and that form II is the more thermodynamically stable form
has been confirmed by competitive slurry with temperature cycling [25].
The observation of polymorphism in a co-crystal system is not in itself unusual; several authors
have surveyed both the literature and the CSD for examples of polymorphic co-crystal systems, and a
recent survey by Mnguni et al. [26] reported 125 such systems involving APIs. However, it is less
common to find polymorphism arising from the use of both solid-state and liquid-state crystallizations,
as is the case with CBZ:IND.
5. Conclusions
Structure determination from powder diffraction data is an extremely valuable tool for elucidating
co-crystal structures, and dispersion-corrected density functional theory is an increasingly valuable
adjunct [27–29], not only for crystal structure validation but also as part of crystal structure
refinement [30]. Its value in mechanochemical synthesis is very well illustrated by the case of
FUR:URE, where the crystal form was reported in 2012 but not elucidated, because of the absence
of a single-crystal. The rigid-body approach to Rietveld refinement has much to commend it, as it
preserves core geometric features of the high-quality input models that are ideally used when solving
structures using global optimization-based methods. However, if (as was the case with CBZ:IND form
II) that core geometry frustrates a successful Rietveld refinement, then DFT-D offers an objective way
to alter that geometry in the context of the crystal structure under study, thus avoiding the need to
employ the more subjective approach of restrained Rietveld refinement. DFT-D also adds considerable
value to the positioning of hydrogen atoms involved in hydrogen bonds. Finally, it should now always
be used as a crystal structure validation tool, according to the guidelines laid down by van de Streek
and Neumann, along with other structure checking tools such as Mogul, PLATON, and checkCIF.
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